1-3 of 3
Mireille Cantarini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Osimertinib plus Selumetinib in EGFR-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)

James Chih-Hsin Yang, Yuichiro Ohe, Chao-Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Jänne, Ryan J. Hartmaier, Myung Ju Ahn
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4222–4231.
https://doi.org/10.1158/1078-0432.CCR-21-4329
Published: 03 October 2022
View article titled, Osimertinib plus Selumetinib in <em>EGFR</em>-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
Open the PDF for Osimertinib plus Selumetinib in <em>EGFR</em>-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B) in another window
Includes: Supplementary data
Journal Articles

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Peter Ballard, James W.T. Yates, Zhenfan Yang, Dong-Wan Kim, James Chih-Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, Mike Hickey, Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne, Darren Cross
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (20): 5130–5140.
https://doi.org/10.1158/1078-0432.CCR-16-0399
Published: 13 October 2016
View article titled, Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Open the PDF for Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity in another window
Includes: Supplementary data
Journal Articles

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 555–567.
https://doi.org/10.1158/1078-0432.CCR-11-1491
Published: 16 January 2012
View article titled, Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
Open the PDF for Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma in another window
Includes: Supplementary data